Cyclodextrin-based pharmaceutics: Past, present and future

Nature Reviews Drug Discovery

Volumn 3, Issue 12, 2004, Pages 1023-1035

  Davis, Mark E ^a   Brewster, Marcus E ^b  

^a California Institute of Technology   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CYCLODEXTRIN; ALPROSTADIL ALPHADEX; BENEXATE; BETA CYCLODEXTRIN; CEFOTIAM; CEFOTIAM HEXETIL; CYCLODEXTRIN; CYTOCHROME P450; DEXAMETHASONE; DICLOFENAC; ERGOSTEROL; ESTRADIOL; EXCIPIENT; GAMMA CYCLODEXTRIN; GLYMESASON; IODINE; ITRACONAZOLE; LIMAPROST; MENA GARGLE; NONSTEROID ANTIINFLAMMATORY AGENT; OLIGOMER; OLIGOSACCHARIDE; OPALMON; OXYTOCIN; PIROXICAM; PIROXICAM BETA CYCLODEXTRIN; PRORENAL; PROSTAGLANDIN; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTAVASIN; SEX HORMONE; SILDENAFIL; UNINDEXED DRUG; WATER;

AREA UNDER THE CURVE; BIOCOMPATIBILITY; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG OXIDATION; DRUG SAFETY; DRUG STABILITY; ERECTILE DYSFUNCTION; EXCIPIENT COMPATIBILITY; GENE DELIVERY SYSTEM; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNE RESPONSE; LABOR INDUCTION; PAIN; PRIORITY JOURNAL; REVIEW; SOLUBILITY; STRUCTURE ANALYSIS; THREE DIMENSIONAL IMAGING; TRANSDERMAL PATCH;

ANIMALS; BIOPHARMACEUTICS; CYCLODEXTRINS; DRUG DELIVERY SYSTEMS; EXCIPIENTS; FORECASTING; HUMANS;

EID: 10444279209     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1576     Document Type: Review

References (161)

1. Atwood, J. L. et al. (eds). Comprehensive Supramolecular Chemistry Vol. 3: Cyclodextrins (Pergamon, New York, 1996).
2. Villiers, A. Sur la fermentation de la fecule par l'action du ferment butyrique. C. R. Hebd. Seances Aced. Sci. 112, 536 (1891).
3. Freudenberg, K., Cramer, F. & Plieninger, H. Verfahren zur Herstellung von Einschlussverbindungen physiologisch wirksamer organischer Verbindungen. German Pat. 895,769 (1953).
4. Qi, Z. H. & Sikorski, C. T. Controlled delivery using cyclodextrin technology. Am. Chem. Soc. Symp. Ser. 728, 113-130 (1999).
5. Frank, D. W., Gray, J. E. & Weaver, R. N. Cyclodextrin nephrosis in rat. Am. J. Pathol. 83, 367-382 (1976).
6. Matsuda, K. et al. Oyo Yakuri 26, 287 (1983); and Chem. Abs. 100, 699 (1984).
7. Szejtli, J. Medicinal applications of cyclodextrins. Med. Res. Ref. 14, 353-386 (1994).
8. Rajewski, R. A. & Stella, V. J. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J. Pharm. Sci. 85, 1142-1169 (1996).
9. Irie, T. & Uekama, K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci. 86, 147-162 (1997).
10. Stella, V. J. & Rajewski, R. A. Cyclodextrins: their future in drug formulation and delivery. Pharm. Res. 14, 556-567 (1997).
11. Uekama, K., Hirayama, F. & Irie, T. Cyclodextrin drug carrier systems. Chem. Rev. 98, 2045-2076 (1998).
12. Hirayama, F. & Uekama, K. Cyclodextrin-based controlled drug release system. Adv. Drug Del. Rev. 36, 125-141 (1999).
13. Arima, H., Hirayama, F., Okamoto, C. T. & Uekama, K. Recent aspects of cyclodextrin-based pharmaceutical formulations. Recent Res. Devel. Chem. Pharm. Sci. 2, 155-193 (2002).
14. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3-25 (1997).
15. Lipinski, C. A. Avoiding investment in doomed drugs. Curr. Drug Discov. 1, 17-19 (2001).
16. Prentis, R. A., Lis, Y. & Walker, S. R. Pharmaceutical innovation by seven UK-owned pharmaceutical companies (1964-1985). Br. J. Clin. Pharmacol. 25, 387-396 (1988).
17. Amidon, G. L., Lennernäs, H., Shah, V. P. & Cirson, J. R. Theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12, 413-A20 (1995).
18. Dressman, J. B., Amidon, G., Reppas, C. & Shah, V. P. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 15, 11-22 (1998).
19. Ahr, G., Voith, B. & Kuhlmann, J. Guidance related to bioavailability and bloequivalence: European industry perspective. Eur. J. Drug Metab. Pharmacokinet. 25, 25-27 (2000).
20. Loftsson, T. Cyclodextrins and the biopharmaceutical classification system of drugs. J. Incl. Phenom. Macrocycl. Chem. 44, 63-67 (2002).
21. Strickley, R. G. Solubilizing excipients in oral and injectable formulation. Pharm. Res. 21, 201-230 (2004).
22. Dressman, J., Butler, J., Hempenstall, J. & Reppas, C. The BCS: where do we go from here? Pharm. Tech. 25, 68-76 (2001).
23. Pagington, J. S. β-Cyclodextrin: the success of molecular inclusion. Chem. Brit. 23, 455-458 (1987).
24. Uekama, K., Hirayama, F. & Irie, T. Cyclodextrin drug carrier systems. Chem. Rev. 98, 2045-2076 (1998).
25. Thompson, D. O. Cyclodextrins - enabling excipents: their present and future use in pharmaceuticals. Crit. Rev. Ther. Drug Carrier Syst. 14, 1-104 (1997).
26. Loftsson, T. & Brewster, M. E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 85, 1017-1025 (1996).
27. Uekama, K. & Otagiri, M. Cyclodextrins in drug carrier systems. Crit. Rev. Ther. Drug Carrier Syst. 3, 1-40 (1987 ).
28. Loftsson, T., Brewster, M. E. & Masson, M. Role of cyclodextrins in improving oral drug delivery. Am. J. Drug Deliv., (in the press).
29. Tsuboshima, M., Matsumoto, K., Aral, Y., Wakatsuka, H. & Kawasaki, A. Prostaglandins: synthetic and pharmaceutical studies and development. Yakugaku Zasshi 112, 447-469 (1992).
30. Inaba, K. Application of cyclodextrin to prostaglandin formulation. Denpun Kagaku 31, 107-111 (1984).
31. Shabsigh, R. et al. Intracavernous alprostadil alfadex is more efficacious, better tolerated and preferred over intraurethral alprostedil plus optional actis: a comparative, randomized, crossover, multicenter study. Urology 55, 109-113 (2000).
32. 1 and penile implant surgery for erectile dysfunction in urology practice. J. Urol. 170, 159-163 (2003).
33. Buvat, J. et al. Double-blind multicenter study comparing alprostabil α-cyclodextrin with moxisylyte hydrochloride in patients with chronic erectile dysfunction. J. Urol. 159, 116-119 (1998).
34. Goldstein, I. et al. Axial penile rigidity as primary efficacy outcome during multi-institutional in-office dose titration clinical trials with alprostadil alfadex in patients with erectile dysfunction. Int. J. Impot. Res. 12, 205-211 (2000).
35. Shabsigh, R. et al. Intracavernous alprostadil alfadex (Edex/Viridal) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra). Urology 55, 477-480 (2000).
36. Nakai, K. et al. Effects of OP-1206 α-CD on walking dysfunction in the rat neuropathic intermittent claudication model: comparison with nifedipine, ficlopidine and cilostazol. Prostag. Oth. Lipid M. 71, 253-263 (2003).
37. 1 analog. J. Histochem. Cytochem. 45, 63-70 (1997).
38. Brooks, P. Use and benefits of nonsteroidal anti-inflammatory drugs. Am. J. Mad. 104, S9-S13 (1998).
39. Bjarnason, I., Takeuchi, K. & Simpson, R. NSAIDs: the emperor's new dogma? Gut 52, 1376-1378 (2003).
40. Wiseman, E. H. Pharmacologic studies with a new class of nonsteroidal anti-inflammatory agents - the oxicams - with special reference to piroxicam (Feldene). Am. J. Med. 72, 2-8 (1982).
41. Ando, G. A. & Lombardona, J. G. Piroxicam - a literature review of new results from laboratory and clinical studies. Eur. J. Rheumatol. Inflamm. 6, 2-23 (1983).
42. Fenner, H. Pharmacokinetics of piroxicam: new aspects. Eur. J. Rheumatol. Inflamm. 8, 42-48 (1987).
43. Olkkola, K., Brunetto, A. & Mattila, M. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clin. Pharmacokinet. 26, 107-120 (1994).
44. Giordano, F. & Bettini, R. Process for preparation of inclusion compounds between a non-steroidal anti-inflammatory drug and β-cyclodextrin by microwave treatment. WO053475 (2003).
45. Caril, F. & Chiesi, P. Process for preparing piroxicam/cyclodextrin complexes, the products obtained and their pharmaceutical compositions. EP0449167 (1991).
46. Capocchi, A. A process for the preparation of piroxicam: β-cyclodextrin inclusion compounds. WO03105906 (2003).
47. Redenti, E. et al. A study on the differentiation between amorphous piroxicam:β-cyclodextrin complex and a mixture of the two amorphous components. Int. J. Pharm. 129, 289-294 (1996).
48. McEwen, J. Clinical pharmacology of piroxicam-β-cyclodextrin. Implications for innovative patient care. Clin. Drug Invest. 19 (Suppl. 2), 27-31 (2000).
49. Woodcock, B. G., Acerbi, D., Merz, P. G., Rietbrock, S. & Rietbrock, N. Supermolecular inclusion of piroxicann with β-cyclodextrin: pharmacokinetic properties in man. Eur. J. Rheumatol. Inflamm. 12, 12-28 (1993).
50. Serni, U. Rheumatic disease - clinical experience with piroxicam-β-cyclodextrin. Eur. J. Rheumatol. Inflamm. 12, 47-54 (1993).
51. Lee, C. R. & Balfour, J. A. Piroxicam-β-cyclodextrin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in rheumatic diseases and pain states. Drugs 48, 907-929 (1994).
52. Santucci, L. et al. Placebo-controlled comparison of piroxicam-β-cyclodextrin, piroxicam and indomethacin on gastric potential differences and mucosal injury in humans. Digest. Dis. Sci. 37, 1825-1832 (1992).
53. Patoia, F. et al. Comparison of fecal blood loss, upper gastrointestinal mucosal integrity and symptoms after piroxicam β-cyclodextrin, piroxicam and placebo administration. Eur. J. Clin. Pharmacol. 36, 599-604 (1989).
54. Nervetti, A., Ambanelli, U. & Ugolotti, G. Assessment of gastric mucosal damage by a new inclusion complex of piroxicam with β-cyclodextrin: a functional study by a scintigraphic method. J. Drug Develop. 1 (Suppl. 1), 39-42 (1991).
55. Szente, L. & Szejtli, J. Highly soluble cyclodextrin derivatives: chemistry, properties and trends in development. Adv. Drug Deliv. Rev. 36, 17-28 (1999).
56. Studd, J. et al. Efficacy and acceptability of intranasal 17 β-estradiol for menopausal symptoms: randomized dose-response study. Lancet 353, 1574-1578 (1999).
57. Pelissier, C. et al. Clinical evaluation, dose-finding and acceptability of Aerodiol, the pulsed estrogen therapy for treatment of climacteric symptoms. Maturitas 37, 181-189 (2001).
58. Gompel, A. et al. Endometrial safety and tolerability of Aerodiol (intranasal estradiol) for 1 year. Maturitas 36, 209-215 (2000).
59. Panay, N., Toth, K., Pelissier, C. & Studd, J. Dose-ranging studies of a novel intranasal estrogen replacement therapy. Maturitas 38 (Suppl. 1), S15-S22 (2001).
60. Doren, M. et al. Therapeutic value and long-term safety of pulsed estrogen therapy. Maturitas 38 (Suppl. 1), S23-S30 (2001).
61. Welnicka-Jaskiewicz, M. & Jassem, J. The risks and benefits of hormonal replacement therapy in healthy women and in breast cancer survivors. Cancer Treat. Rev. 29, 355-361 (2003).
62. Kahn, N. & Malhotra, S. Effect of hormone replacement therapy on cardiovascular disease, current opinion. Exp. Opin. Pharmacother. 4, 667-674 (2003).
63. Henzl, M. R. & Loomba, P. K. Transdermal delivery of sex steroids for hormonal replacement therapy and contraception: a review of principles and practice. J. Reprod. Med. 48, 525-540 (2003 ).
64. Stevenson, J. C. Optimizing delivery systems for HRT Maturitas 33 (Suppl. 1), S31-S38 (1999).
65. Montgomery Rice, V. Optimizing the dose of hormone replacement therapy. Int. J. Fertil. Womens Med. 47, 205-211 (2002).
66. Albers, F. & Muller, B. W. Cyclodextrin derivatives in pharmaceutics. Crit. Rev. Ther. Drug Carrier Syst. 12, 311-337 (1995).
67. Brewster, M. E., Simpkins, J. W., Hora, M. S., Stern, W. C. & Bodor N. The potential use of cyclodextrins in parenteral formulations. J. Parenter. Sci. Technol. 43, 231-240 (1989).
68. Mosher, G. & Thompson, D. O. Complexation and cyclodextrins. Encyclopedia of Pharmaceutical Technology, 531-558 (2002).
69. Loftsson, T. & Brewster, M. E. Cyclodextrins as pharmaceutical excipients. Pharm. Tech. Eur. 9, 26-34 (1997).
70. Mester, U. et al. A comparison of two different formulations of diclofenac sodium 0.1% in the treatment of inflammation following cataract-intraocular lens surgery. Drugs R&D 3, 143-151 (2002).
71. Peeters, J., Neeskens, P., Tollenaere, J. P., Van Remoortere, P. & Brewster, M. E. Characterization of the interaction of 2-hydroxyloropyl-β-cyclodextrin with itraconazole at pH 2, 4 and 7. J. Pharm. Sci. 91, 1414-1422 (2002).
72. Be Beule, K. Itraconazole: pharmacology, clinical experience and future development. Int. J. Antimicrob. Agents 6, 175-181 (1996).
73. Negroni, R. & Arechavala, A. I. Itraconazole: pharmacokinetic and indications. Arch. Med. Res. 24, 387-393 (1993).
74. Pierard, G. E., Arrese, J. E. & Pierard-Franchimont, C. Itraconazole. Expert Opin. Pharmacother. 1, 287-304 (2000).
75. Jain, S. & Sehgal, V. N. Itraconazole: an effective oral antifungal for onchomycosis. Int. J. Dermatol. 40, 1-5 (2001).
76. Verreck, G., Chun, I., Peeters, J., Rosenblatt, J. & Brewster, M. Preparation and characterization of nanofibers containing amorphous drug dispersions generated by electrostatic spinning. Pharm. Res. 20, 810-817 (2003).
77. Vandecruys, R., De Conde, V., Gillis, P. & Peeters, J. Pellets having a core coated with an antifungal and a polymer. WO9842318 (1998).
78. Jaruratanasirikul, S. & Kleepkaew. A. Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole Eur. J. Clin. Pharmacol. 52, 235-237 (1997).
79. Grant, E. M. Optimizing the bioavailability of itraconazole. Conn. Med. 64, 415-417 (2000).
80. Welage, L. S., Carver, P. L., Revankar, S., Pierson, C. & Kauffman, C. A. Alterations in gastric acidity in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 21, 1431-1438 (1995).
81. De Beule, K. & Van Gestel, J. Pharmacology of itraconazole. Drugs 61 (Suppl. 1), 27-33 (2001).
82. Slain, D., Rogers, P. D., Cleary, J. D. & Chapman, S. W. Intravenous itraconazole. Ann. Pharmacother. 35, 720-729 (2001).
83. Willems, L., Van der Geest, R. & De Beule, K. Itraconazole oral solution and intravenous formulations: A review of pharmacokinetics and pharmacodynamics. J. Clin. Pharm. Ther. 26, 159-169 (2001).
84. Physician's Desk Reference
85. Brewster, M. E. et al. The use of polymer-based electrospun nanofibers containing amorphous drug dispersions in the delivery of poorly water-soluble pharmaceuticals. Pharmazie 59 387-391 (2004).
86. 7M-β-CD to HP-β-CD. Pharm. Res. 18, 667-673 (2001).
87. Rajewski, R. A. et al. Preliminary safety evaluation of parenterally administered sulfoalkyl ether β-cyclodextrin derivatives. J. Pharm. Sci. 84, 927-932 (1995).
88. Kim, Y. et al. Inclusion complexation of ziprasidone mesylate with β-cyclodextrin sulfobutyl ether. J. Pharm. Sci. 87, 1560-1567 (1998).
89. Jeu, L., Piacenti, F. J., Lyakhovetskiy, A. G. & Fung, H. B. Voriconazole. Clin. Ther. 25, 1321-1381 (2003).
90. Purkins, L., Wood, N., Greenhalgh, K., Allen, M. J. & Oliver, S. D. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br. J. Clin. Pharmacol. 56, 10-16 (2003).
91. Purkins, L. et al. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent. Br. J. Clin. Pharmacol. 56, 2-9 (2003).
92. Harding, V. D. Pharmaceutical formulations containing voriconazole. WO9858677 (1998).
93. FDA Website (http://www.fda.gov/)
94. Irie, T. & Uekama, K. Cyclodextrin in peptide and protein delivery. Adv. Drug Deliv. Rev. 36, 101-123 (1999).
95. Cserhati, T., Forgacs, E. & Szejtli, J. Inclusion complex formation of antisense nucleotides with hydroxypropyl-β -cyclodextrin. Int. J. Pharm. 141, 1-7 (1996).
96. Zhao, Q., Temsamani, J. & Agrawal, S. Use of cyclodextrin and its derivatives as carriers for oligonucleotide delivery. Antisense Res. Dev. 5, 185-192 (1995).
97. Redenti, E., Pietra, C., Gerloczy, A. & Szente, L. Cyclodextrins in oligonucleotide delivery. Adv. Drug Deliv. Res. 53, 235-244 (2001).
98. Brewster, M., Simpkins, J., Fore, M. & Bodor, N. Use of 2-hydroxypropyl-β-cyclodextrin as a solubilizing and stabilizing excipient for protein drugs. Pharm. Res. 8, 792-795 (1991).
99. Charman, S. A., Mason, K. L. & Charman, W. N. Techniques for assessing the effect of pharmaceutical excipients on aggregation of porcine growth hormone. Pharm. Res. 10, 954-962 (1993).
100. Leung, D. K., Yang, Z. & Breslow, R. Selective disruption of protein aggregation by cyclodextrin dimers. Proc. Natl Acad. Sci. USA 97, 5050-5053 (2000).
101. Rozema, D. & Gellman, S. Artificial chaperone-assisted refolding of denatured-reduced lysozyme: modulation of the competition between renaturation and aggregation. Biochemistry-US 35, 15760-15771 (1996).
102. Rozema, D. & Gellman, S. Artificial chaperone-assisted refolding of carbonic anhydrase B. J. Biol. Chem. 271, 3478-3487 (1996).
103. Rozeman, D. & Gellman, S. H. Artificial chaperones: protein refolding via sequential use of detergent and cyclodextrin. J. Am. Chem. Soc. 117, 2373-2374 (1995).
104. Couthon, F., Clottes, E. & Vial, C. Refolding of SDS- and thermally denatured MM-creathe kinase using cyclodextrins. Biochem. Biophys. Res. Commun. 227, 854-860 (1996).
105. Liao, Z., Graham, D. & Hildreth, J. E. K. Lipid rafts and HIV pathogenesis: viron-associated cholesterol is required for fusion and infection of susceptible cells. AIDS Res. Human Retroviruses 19 675-687 (2003).
106. Graham, D., Chertova, E., Hilburn, J., Arthur, L. & Hildreth, J. E. K. Cholesterol depletion of human immunodeficiency virus type 1 and simian immunodeficiency virus with β-cyclodextrin inactivates and permeabilizes the virons: evidence for viron-associated lipid rafts. J. Virol. 77, 8237-8248 (2003).
107. Bom, A. et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew. Chem. Int. Ed. Engl. 41, 266-270 (2002).
108. Loftsson, T. & Másson, M. The effects of water-soluble polymers on cyclodextrins and cyclodextrin solubilization of drugs. J. Drug Deliv. Sci. Tech. 14, 35-43 (2004).
109. Yue, I. C. et al. A novel polymeric chlorhexidine delivery device for the treatment of periodontal disease. Biomaterials 25, 3743-3750 (2004).
110. Huang, L. et al. Formation of antibiotic, biodegradable/bioadsorbable polymers by processing with neomycin sulfate and its inclusion compound with β-cyclodextrin. J. Appl. Poly. Sci. 74, 937-947 (1999).
111. Lu, J. et al. Formation of antibiotic, biodegradable polymers processing with Irgasan DP300R (Triclosan) and its inclusion compound with β-cyclodextrin. J. Appl. Poly. Sci. 82, 300-309 (2001)
112. Rusa, C. C. et al. Controlling the behaviors of biodegradable/bioadsorbable polymers with cyclodextrins. J. Polym. Environ. 12, 157 (2004).
113. Kis, G., Schoch, C. & Bizec, J.-C. Quaternary ammonium cyclodextrins - molecules with a wide range of applications. 12th International Cyclodextrin Symposium (Montpellier, France), P-203, May 16-19, 2004.
114. Szeman, J. et al. Water soluble cyclodextrin polymers: their interaction with drugs. J. Inclus. Phenom. 5, 427-431 (1987).
115. Szeman, J. et al. Complexation of several drugs with water-soluble cyclodextrin polymer. Chem. Pharm. Bull. 35, 282-288 (1987).
116. Fenyvesi, E., Ujházy, A., Szejtli, J., Pütter, S. & Gan, T. G. Controlled release of drugs from CD polymers substituted with ionic groups. J. Inclus. Phenom. Mol. 25, 185-189 (1996).
117. Fenyvesi, E. Cyclodextrin polymers in pharmaceutical industry. J. Inclus. Phenom. 6, 537-545 (1988).
118. Mocanu, G., Vizitiu, D. & Carpov, A. Cyclodextrin polymers. J. Bioact. Compat. Pol. 16, 315-342 (2001).
119. Solms, J., & Egli, R. H. Harze mit Einschlusshohlraumen von cyclodextrin-struktur. Helv. Chim. Acta 48, 1225-1228 (1965).
120. Ma, M. & Li, D.-Q. New organic nanoporous polymers and their inclusion complexes. Chem. Mater. 11, 872-874 (1999).
121. Daoud-Mahammed, S. et al. Original tamoxifen-loaded gels containing cyclodextrins: in situ self-assembling systems for cancer treatment. J. Drug. Del. Sci. Tech. 14, 51-55 (2004 ).
122. Li, J., Xiao, H., Li, J. & Zhong, Y. Drug carrier systems based on water-soluble cationic β-cyclodextrin polymers. Int. J. Pharm. 278, 329-342 (2004).
123. Daoud-Mahammed, S. et al. Original tamoxifen-loaded gels containing cyclodextrins: in situ self-assembling systems for cancer treatment. J. Drug Del. Sci. Tech. 14, 51-55 (2004).
124. Harada, A., Furue, M. & Nozakura, S.-I. Cyclodextrin-containing polymers. 1. Preparation of polymers. Macromolecules 9, 701-704 (1976).
125. Harada, A., Furue, M. & Nozakura, S.-I. Inclusion of aromatic compounds by a β-cyclodextrin-epichlorohydrin polymer. Polym. J. 13, 777-781 (1981).
126. Seo, T., Kajihara, T. & Iijima, T. The synthesis of poly(allylamine) containing covalently bound cyclodextrin and its catalytic effect in the hydrolysis of phenyl-esters. Makromol. Chem. 188, 2071-2082 (1987).
127. Ruebner, A., Statton, G. L. & James, M. R. Synthesis of a linear polymer with pendent γ-cyclodextrins. Macromol. Chem. Phys. 201, 1185-1188 (2000).
128. Bachmann, F., Höpken, J., Kohli, R., Lohmann, D. & Schneider, J. Synthesis and polymerization of carbamate-linked cyclodextrin methacrylate monomers. J. Carbohyd. Chem. 17, 1359-1375 (1998).
129. Tojima, T. et al. Preparation of an α-cyclodextrin-linked chitosan derivative via reductive amination strategy. J. Polym. Sci. A 36, 1965-1968 (1998).
130. Tanida, F. et al. Novel synthesis of a water-soluble cyclodextrin-polymer having a chitosan skeleton. Polymer 39, 5261-5263 (1998).
131. Weickenmeier, M. & Wenz, G. Cyclodextrin sidechain polyesters - synthesis and inclusion of adamantan derivatives. Macromol. Rapid Commun. 17, 731-736 (1996).
132. Suh, J., Lee, S.-H. & Zoh, K. D. A novel host containing both binding site and nucleophile prepared by attachment of β -cyclodextrin to poly(ethylenimine). J. Am. Chem. Soc. 114, 7916-7917 (1992).
133. Pun, S. H. et al. Cyclodextrin-modified polyethylenimine polymers for gene delivery. Bioconjug. Chem. 15 831-840 (2004).
134. Suh, J., Hah, S. S. & Lee, S. H. Dendrimer poly(ethylenimine)s linked to β-cyclodextrin. Bioorg. Chem. 25 63-75 (1997).
135. Arima, H., Khara, F., Hiryama, F. & Uekama, K. Enhancement of gene expression by polyamidoamine dendrimer conjugates with α-, β-, and γ-cyclodextrins. Bioconjug. Chem. 12, 476-484 (2001).
136. Kihara, F., Arima, H., Tsutsumi, T., Hirayama, F. & Uekama, K. Effects of structure of polyamidoamine dendrimer on gene transfer efficiency of the dendrimer conjugate with α-cyclodextrin. Bioconjug. Chem. 13, 1211-1219 (2002).
137. Kihara, F., Arima, H., Tsutsumi, T., Hirayama, F. & Uekama, K. In vitro and in vivo gene transfer by an optimized α-cyclodextrin conjugate with polyamidoamine dendrimer. Bioconjug. Chem. 14, 342-350 (2003).
138. Newkome, G. R., Godínez, L. A. & Moorefield, C. N. Molecular recognition using β-cyclodextrin-modified dendrimers: novel building blocks for convergent self-assembly. Chem. Commun. 1821-1822 (1998).
139. Baussanne, I. et al. Synthesis and comparative lectin-binding affinity of mannosyl-coated β-cyclodextrin-dendrimer constructs. Chem. Commun. 1489-1490 (2000).
140. Ohno, K., Wong, B. & Haddelton, D. M. Synthesis of well-defined cyclodextrin-core star polymers. J. Polym. Sci. A 39, 2206-2214 (2001).
141. Harada, A., Furue, M. & Nozakura, S. Cyclodextrin-containing polymers. 2. Cooperative effects in catalysis and binding. Macromolecules 9, 705-709 (1976).
142. Harada, A., Furue, M. & Nozakura, S. Inclusion of aromatic-compounds by a β-cyclodextrin-epichlorohydrin polymer. Polym. J. 13, 777-781 (1981).
143. Asanuma, H., Kakazu, M., Shibata, M., Hishiya, T. & Komiyama, M. Molecularly imprinted polymer of β-cyclodextrin for the efficient recognition of cholesterol. Chem. Commun. 1971-1972 (1997).
144. Gonzalez, H., Hwang, S. J. & Davis, M. E. New class of polymers for the delivery of macromolecular therapeutics. Bioconjug. chem. 10, 1068-1074 (1999).
145. Hwang, S. J., Bellocq, N. C. & Davis, M. E. Effects of structure of β-cyclodextrin-containing polymers on gene delivery. Bioconjug. Chem. 12, 280-290 (2001).
146. Pun, S. H. & Davis, M. E. Development of a nonviral gene delivery vehicle for systemic application. Bioconjug. Chem. 13 630-639 (2002).
147. Reineke, T. M. & Davis, M. E. Structural effects of carbohydrate-containing polycations on gene delivery. 1. Carbohydrate size and its distance from charge centers. Bioconjug. Chem. 14 247-254 (2003).
148. Reineke, T. M. & Davis, M. E. Structural effects of carbohydrate-containing polycations on gene delivery. 2. Charge center type. Bioconjug. Chem. 14, 255-261 (2003).
149. Popielarski, S. R., Mishra, S. & Davis, M. E. Structural effects of carbohydrate-containing polycations on gene delivery. 3. Cyclodextrin type and functionalization. Bioconjug. Chem. 14, 672-678 (2003).
150. Bellocq, N. C., Pun, S. H., Jensen, G. S. & Davis, M. E. Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug. Chem. 14, 1122-1132 (2003).
151. Cheng, J., Khin, K. T., Jensen, G. S., Liu, A. & Davis, M. E. Synthesis of linear, β-cyclodextrin-based polymers and their camptothecin conjugates. Bioconjug. Chem. 14, 1007-1017 (2003).
152. Cheng, J., Khin, K. T. & Davis, M. E. Antitumor activity of β-cyclodextrin polymer-camptothecin conjugates. Mol. Pharm. 1 183-193 (2004).
153. Davis, M. E. et al. Self-assembling nucleic acid delivery vehicles via linear, water-soluble, cyclodextrin-containing polymers. Curr. Med. Chem. 11, 1241-1253 (2004).
154. Pun, S. H. et al. Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles. Cancer Biol. Ther. 3, 31-40 (2004).
155. Cryan, S. A., Holohan, A., Donohue, R., Darcy, R. & O'Driscoll, C. M. Cell transfection with polycationic cyclodextrin vectors. Eur. J. Pharm. Sci. 21, 625-633 (2004).
156. Cryan, S. A., Donohue, R., Ravoo, B. J., Darcy, R. & O'Driscoll, C. M. Cationic cyclodextrin amphiphiles as gene delivery vectors. J. Drug Deliv. Sci. Tech. 14, 57-62 (2004).
157. Wolff, J. A. et al. Compositions and methods for drug delivery using amphiphile binding molecules. US Pat 6,740,643 (2004).
158. Amiel, C., Galant, C. & Auvray, L. Ternary complexes involving β-cyclodextrin polymer, a cationic surfactant and an anionic polymer. Prog. Colloid Polym. Sci. 126 (in the press).
159. Zanta, M. A., Boussif, O., Adib, A. & Behr, J. P. In vitro gene delivery to hepatocytes with galactosylated polyethylenimine. Bioconjug. Chem. 8, 839-844 (1997).
160. Forrest, M. L., Meister, G. E., Koerber, J. T. & Pack, D. W. Partial acetylation of polyethylenimine enhances in vitro gene delivery. Pharm. Ras. 21, 365-371 (2004).
161. Thomas, M. & Klibanov, A. M. Enhancing polyethylenimine's delivery of plasmid DNA into mammalian cells. Proc. Natl Acad. Sci. USA 99, 14640-14645 (2002).